170 323

Cited 0 times in

Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer

DC FieldValueLanguage
dc.contributor.author장준-
dc.contributor.author정경영-
dc.contributor.author최병욱-
dc.contributor.author허진-
dc.contributor.author홍유진-
dc.contributor.author김세규-
dc.contributor.author김영진-
dc.contributor.author김주항-
dc.contributor.author김희영-
dc.contributor.author남지은-
dc.contributor.author이혜선-
dc.contributor.author이혜정-
dc.date.accessioned2014-12-19T16:34:10Z-
dc.date.available2014-12-19T16:34:10Z-
dc.date.issued2012-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/89776-
dc.description.abstractBACKGROUND: Cytological fluid from a needle aspiration biopsy (NAB) is obtained directly from tumor tissue, therefore many biomarker candidates will be present in high concentrations. The aim of this study was to prospectively assess and validate the tumor markers CYFRA 21-1, CEA, and SCC in cytological fluid obtained from NAB samples to determine if they improved the performance of NAB for diagnosing non-small cell lung cancer (NSCLC). METHODS: A total of 194 patients (M:F = 128:66, mean age 63.7 years) with suspected malignant pulmonary lesions were prospectively enrolled and underwent percutaneous NAB. Levels of CYFRA 21-1, CEA, and SCC were measured by immunoassay in serum and cytological fluid obtained during aspiration biopsy. Cut-off values to determined malignancy were 3.3 ng/mL in serum and 15.7 ng/mL in cytological fluid for CYFRA 21-1, 5 ng/mL and 0.6 ng/mL for CEA, and 2 ng/mL and 0.86 ng/mL for SCC. RESULTS: Of 194 patients, 139 patients (71.6%) had NSCLC and 55 (28.4%) had benign lesions. Sensitivity increased significantly for NAB combined with cytological tumor markers compared with NAB alone (CYFRA 21-1: 95% versus 83.5%, p < 0.001, CEA: 92.1% versus 83.5%, p = 0.002, SCC: 91.4% versus 83.5%, p = 0.003). Accuracy improved significantly for NAB combined with cytological CYFRA 21-1 compared with NAB alone (95.9% versus 88.1%, p < 0.001). The area under curve (AUC) of NAB with cytological CYFRA 21-1 was significantly larger than for NAB alone (0.966 versus 0.917, p = 0.009). CONCLUSION: Of the tested tumor markers, cytological fluid measurements of CYFRA 21-1 improved the diagnostic performance of NAB for NSCLC.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfBMC CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAntigens, Neoplasm/blood-
dc.subject.MESHAntigens, Neoplasm/metabolism-
dc.subject.MESHBiomarkers, Tumor/blood-
dc.subject.MESHBiomarkers, Tumor/metabolism*-
dc.subject.MESHBiopsy, Needle-
dc.subject.MESHCarcinoembryonic Antigen/blood-
dc.subject.MESHCarcinoembryonic Antigen/metabolism-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/diagnosis*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/metabolism-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/pathology-
dc.subject.MESHExtracellular Fluid/metabolism*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHKeratin-19/blood-
dc.subject.MESHKeratin-19/metabolism-
dc.subject.MESHLung Neoplasms/diagnosis*-
dc.subject.MESHLung Neoplasms/metabolism-
dc.subject.MESHLung Neoplasms/pathology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHROC Curve-
dc.subject.MESHReproducibility of Results-
dc.subject.MESHSerpins/blood-
dc.subject.MESHSerpins/metabolism-
dc.titleAdditional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentYonsei Biomedical Research Center (연세의생명연구원)-
dc.contributor.googleauthorJin Hur-
dc.contributor.googleauthorHye-Jeong Lee-
dc.contributor.googleauthorJi Eun Nam-
dc.contributor.googleauthorYoung Jin Kim-
dc.contributor.googleauthorYoo Jin Hong-
dc.contributor.googleauthorHee Yeong Kim-
dc.contributor.googleauthorSe Kyu Kim-
dc.contributor.googleauthorJoon Chang-
dc.contributor.googleauthorJoo-Hang Kim-
dc.contributor.googleauthorKyung Young Chung-
dc.contributor.googleauthorHye Sun Lee-
dc.contributor.googleauthorByoung Wook Choi-
dc.identifier.doi22954172-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03472-
dc.contributor.localIdA03571-
dc.contributor.localIdA04059-
dc.contributor.localIdA04370-
dc.contributor.localIdA04422-
dc.contributor.localIdA00602-
dc.contributor.localIdA00945-
dc.contributor.localIdA01213-
dc.contributor.localIdA01269-
dc.contributor.localIdA00727-
dc.contributor.localIdA03312-
dc.contributor.localIdA03320-
dc.relation.journalcodeJ00351-
dc.identifier.eissn1471-2407-
dc.identifier.pmid22954172-
dc.subject.keywordCytokeratin 19 fragments (CYFRA 21–1)-
dc.subject.keywordCarcinoembryonic antigen (CEA)-
dc.subject.keywordSquamous cell carcinoma antigen (SCC)-
dc.subject.keywordNeedle aspiration biopsy (NAB)-
dc.subject.keywordTumor marker-
dc.subject.keywordCytological fluid-
dc.subject.keywordNon-small cell lung cancer (NSCLC)-
dc.contributor.alternativeNameChang, Joon-
dc.contributor.alternativeNameChung, Kyung Young-
dc.contributor.alternativeNameChoi, Byoung Wook-
dc.contributor.alternativeNameHur, Jin-
dc.contributor.alternativeNameHong, Yoo Jin-
dc.contributor.alternativeNameKim, Se Kyu-
dc.contributor.alternativeNameKim, Young Jin-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameKim, Hee Yeong-
dc.contributor.alternativeNameNam, Ji Eun-
dc.contributor.alternativeNameLee, Hye Sun-
dc.contributor.alternativeNameLee, Hye Jeong-
dc.contributor.affiliatedAuthorChang, Joon-
dc.contributor.affiliatedAuthorChung, Kyung Young-
dc.contributor.affiliatedAuthorChoi, Byoung Wook-
dc.contributor.affiliatedAuthorHur, Jin-
dc.contributor.affiliatedAuthorHong, Yoo Jin-
dc.contributor.affiliatedAuthorKim, Se Kyu-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorKim, Hee Yeong-
dc.contributor.affiliatedAuthorNam, Ji Eun-
dc.contributor.affiliatedAuthorKim, Young Jin-
dc.contributor.affiliatedAuthorLee, Hye Sun-
dc.contributor.affiliatedAuthorLee, Hye Jeong-
dc.citation.volume12-
dc.citation.startPage392-
dc.identifier.bibliographicCitationBMC CANCER, Vol.12 : 392, 2012-
Appears in Collections:
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.